What we did:
For a molecular testing client, built multi-omic ML models to predict recurrence, survival, disease progression, and to stratify potential responders vs non-responders to immunotherapy.
How it works:
Why it matters:
Augmenting existing molecular test results, comprising of a 20+ gene panel, with an RUO AI prognostic model increased average selling price (ASP) and volume of tests ordered by physicians. On the infrastructure side, we accelerated pre-auths as well as enabled payors, providers, and patients to consume results and RUO report in EPIC.